BioCentury
ARTICLE | Regulation

Looking beyond Avastin

Doctors look ahead to new treatment options for metastatic breast cancer

July 11, 2011 7:00 AM UTC

As clinicians reduce their use of Avastin bevacizumab for metastatic breast cancer, they are looking hopefully toward the more than 24 targeted therapies in Phase II or Phase III trials for metastatic HER2-negative breast cancer.

Some clinicians also suggest Avastin, a mAb against VEGF, could find another spot in this expanding breast cancer armamentarium...